The ANGPTL3 monoclonal antibody, evinacumab, was reported to reduce plasma TG and LDL-C levels in healthy subjects and patients with homozygous familial hypercholesterolemia (18, 30). This evidence concerns the gene ANGPTL3 and familial hypercholesterolemia.